Search Results for “medical devices” – Page 34 – media

Neuralink competitor Paradromics gets one step closer to FDA approval for its brain implant

A growing team of nearly 50 employees at the neurotech startup Paradromics is working on a brain implant that sounds like the work of science fiction. And it has caught the attention of federal regulators. Paradromics, founded in 2015, is developing a device that could help patients with severe paralysis regain their ability to communicate by deciphering their neural signals. And on Thursday, the Austin, Texas-based company announced that it has received the Breakthrough Device designation from the Food and Drug Administration for its flagship system, called the Connexus Direct Data Interface. CEO Matt Angle said the designation, in addition to a $33 million funding round the company also announced Thursday, will help Paradromics bring its device to market. Paradromics is part of the emerging brain-computer interface, or BCI, industry. A BCI is a system that deciphers brain signals and translates them into commands for external technologies. Experts believe the ...
- Source: drugdu
- 122
- May 21, 2023
Abbott expands initiative to increase diversity in clinical trials

May 12, 2023 By Sean Whooley Leave a Comment Abbott (NYSE:ABT) announced a new series of programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care in under-represented populations. The additions to Abbott’s “Diversity in Clinical Trials” initiative build on partnerships, scholarships and the focus on diversified patients. Abbott applied these to its own clinical trials throughout the initiative’s first year. Within that first year, the company established a Diversity in Clinical Trials Medical Advisory Board. Through $5 million in grants, it also sponsored more than 300 scholarships at four historically black colleges and university (HBCU) medical schools, plus the National Black Nurses Association and National Association of Hispanic Nurses. Within this program expansion, Abbott launched a new initiative with the Norton Healthcare Foundation. It aims to build and implement new models of sustainable clinical research alongside the Institute for Health Equity in Louisville, Kentucky. ...
- Source: drugdu
- 138
- May 16, 2023
Maximizing the Value of AI in Cancer Care

Real-time patient experiences is the missing element to most electronic health records, artificial intelligence, and machine learning models today. Anish Patankar, SVP, GM, Oncology Informatics Software, Elekta Cancer treatment has come a long way in recent years and is now evolving more rapidly through the integration of artificial intelligence (AI) tools, such as machine learning (ML). Currently, health data exists in many forms, including electronic health records (EHR), diagnostic images, genomic and molecular data, pharmacological data, and patient-reported data. The creation of state-of-the-art cancer treatments can be enhanced by the ways clinicians leverage data to optimize care, and there’s no better way to achieve this than through the use of AI. Completing the picture There is a missing element to most EHR, AI, and ML models today – real-time patient-reported outcomes. This type of data refers to information regarding patients’ experiences with their medical conditions, treatments, and healthcare providers, ...
- Source: drugdu
- 146
- May 14, 2023
US Supreme Court delays abortion pill access decision

By Nadine Yousif & Robin Levinson-King BBC News The US Supreme Court has extended until Friday a temporary block on limits to access of a popular abortion pill. A Texas judge suspended approval of abortion drug mifepristone on 7 April, questioning its safety. Parts of that decision were upheld on appeal, prompting the Biden administration to make an emergency request to the Supreme Court. It’s the most significant such case since the Supreme Court last year ended the nationwide right to abortion. The pill – used in more than half of abortions in the US – was first approved by the Food and Drug Administration (FDA) more than two decades ago. Here’s how we got here. What has happened so far? Earlier this month, a federal judge in Texas issued a preliminary injunction revoking the FDA’s approval for the drug while he hears a lawsuit brought by a group of ...
- Source: drugdu
- 136
- April 24, 2023
Study Suggests Increased Number of PMA Supplements Increase Recall Risk

Investigators also highlighted long-standing concerns that modified devices may bear little resemblance to the device originally FDA-approved. Katie Hobbins | Apr 19, 2023 Recently, a study published in JAMA Network Open reported that high-risk medical devices whose manufacturers file supplements to the FDA so modifications can be made to PMA-approved products are 30% more likely to be the subject of any recall and high-risk Class I recall. Makers of Class III PMA devices are offered five different types of supplements to allow for product improvements. Only one of the supplements — namely, panel track supplements — actually require clinical evidence for implementation and, as such, are the least-used type of the five, (approximately 1%). In contrast, the most used supplement type is a 30-day notice. A 30-day notice is used when a company makes changes to a manufacturing procedure or the way it makes a device. In the study, investigators analyzed devices approved through ...
- Source: drugdu
- 137
- April 20, 2023
These 3D-printed masks could greatly help pediatric burn patients

April 11, 2023 By Jim Hammerand Leave a Comment FacebookTwitterLinkedIn分享 Burn patients wear the masks on their face to heal scars and prevent complications. “I almost prefer to have the mask on,” said patient Laura Weibel (pictured on the left). [Photo courtesy of Formlabs] 3D-printed masks are removing a traumatic part of treatment for children recovering from severe burns. At Romans Ferrari pediatric rehabilitation center in France, a child with facial burns previously would need to sit motionless for a plaster cast of their face to make a mask for treatment. The masks compress the skin to help scars heal without complications, but the heat from warm plaster bandages can make young burn victims uncomfortable — or worse. “It required the patients to be motionless for the duration of the plaster cast that lasts about half an hour, which can be difficult, especially for children, and could reactivate symptoms of post-traumatic stress ...
- Source: drugdu
- 108
- April 14, 2023
Websites and Tools You Need to Know!

The pharmaceutical foreign trade industry is fiercely competitive, demanding a constant grasp of the latest market information and tech tools to successfully expand business. Today, we're showcasing must-have websites and practical tools for pharmaceutical foreign trade professionals, empowering you to operate more efficiently.
- Source: drugdu
- 233
- March 3, 2023
pharmaceutical foreign trade practical tools
Prioritize, Optimize And Modernize

Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
- Source: https://invivo.pharmaintelligence.informa.com/IV124946/The-PostCOVID-Mantra-For-Medtechs-Prioritize-Optimize-And-Modernize
- 813
- April 6, 2022
Health Care Transformation Modernize Post-COVID Mantra
New NHS Medtech Funding Mandate welcomed by BIVDA

The UK trade association for in vitro diagnostics (IVD) companies BIVDA has welcomed the NHS Medtech Funding Mandate, a new policy aimed at accelerating the uptake of medical devices, diagnostics and digital products in the NHS. The new Mandate, which will come into effect from 1 April 2020, will aim to enable patients to access ‘pioneering’ IVD devices faster and with greater ease. For products to qualify under the Mandate, they must demonstrate that they are effective, deliver material savings to the NHS, are cost-saving in-year and are affordable to the NHS. The Mandate policy is set to be published annually in December, following a review and feedback improvement cycle. A list of technologies that meet the MedTech Funding Mandate criteria is expected to be published before the end of July. “The publication of the Mandate is an opportunity to celebrate the UK as a leader in technologies for health ...
- Source: drugdu
- 248
- January 30, 2021
IVD
FDA Approves First Treatment for COVID-19

For Immediate Release: October 22, 2020 Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered under the EUA, the FDA revised the EUA for Veklury to authorize the drug’s use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to ...
- Source: drugdu
- 258
- October 26, 2020
Covid-19

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.